Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life
Status: | Completed |
---|---|
Conditions: | Infectious Disease |
Therapuetic Areas: | Immunology / Infectious Diseases |
Healthy: | No |
Age Range: | Any |
Updated: | 8/19/2018 |
Start Date: | October 10, 2012 |
End Date: | August 18, 2015 |
Immunogenicity and Safety Study of GSK Biologicals' Priorix Vaccine (209762) at an End of Shelf-life Potency Compared to Merck & Co., Inc.'s Measles-mumps-rubella (MMR) Vaccine When Both Are Given on a 2-dose Schedule to Healthy Children in Their 2nd Year of Life
The purpose of this study is to evaluate end of shelf-life potency in terms of the
immunogenicity and safety of GSK Biologicals' trivalent MMR vaccine, by comparing it to Merck
& Co., Inc.'s MMR vaccine, which is approved for use in the United States (US).
immunogenicity and safety of GSK Biologicals' trivalent MMR vaccine, by comparing it to Merck
& Co., Inc.'s MMR vaccine, which is approved for use in the United States (US).
This trial is a Phase IIIA, randomized, observer-blind, controlled, multi-center,
multi-country study with four parallel groups. This study will evaluate the immunogenicity
and safety of GSK Biologicals' trivalent investigational MMR vaccine (referred to as Inv_MMR
vaccine, throughout this document) in contrast to the US standard of care comparator vaccine
(M-M-R II, Merck and Co., Inc., referred to as Com_MMR throughout this document) in children
during their second year of life. The first dose of this two-dose study is designed to
establish the end of shelf-life potency of Inv_MMR vaccine. The Inv_MMR vaccine will be given
as one of two lots; one of a minimum potency, designated Inv_MMR_Min; and the other at a
mid-range or medium potency designated Inv_MMR_Med to two groups. The second dose for both of
these Inv_MMR groups will have a potency within the release range of the marketed vaccine.
The Com_MMR vaccine will consist of two lots designated Com_MMR_L1 and Com_MMR_L2 and will be
analyzed as pooled lots within the study. The first MMR vaccine dose will be co-administered
with Varivax, Havrix and (in the US sub-cohort only) Prevnar 13 which are routinely
administered to children of this age in the US.
multi-country study with four parallel groups. This study will evaluate the immunogenicity
and safety of GSK Biologicals' trivalent investigational MMR vaccine (referred to as Inv_MMR
vaccine, throughout this document) in contrast to the US standard of care comparator vaccine
(M-M-R II, Merck and Co., Inc., referred to as Com_MMR throughout this document) in children
during their second year of life. The first dose of this two-dose study is designed to
establish the end of shelf-life potency of Inv_MMR vaccine. The Inv_MMR vaccine will be given
as one of two lots; one of a minimum potency, designated Inv_MMR_Min; and the other at a
mid-range or medium potency designated Inv_MMR_Med to two groups. The second dose for both of
these Inv_MMR groups will have a potency within the release range of the marketed vaccine.
The Com_MMR vaccine will consist of two lots designated Com_MMR_L1 and Com_MMR_L2 and will be
analyzed as pooled lots within the study. The first MMR vaccine dose will be co-administered
with Varivax, Havrix and (in the US sub-cohort only) Prevnar 13 which are routinely
administered to children of this age in the US.
Inclusion Criteria:
- Male or female child between 12 and 15 months of age at the time of vaccination.
- The investigator believes that the parent(s) or Legally Acceptable Representative(s)
(LAR(s)) of the child, can, and will comply with the requirements of the protocol.
- Written informed consent obtained from the parent(s)/LAR(s) of the child.
- Child is in stable health as determined by investigator's clinical examination and
assessment of child's medical history.
For US children only:
• Child that previously received a 3-dose series of Prevnar 13 with last dose at least 60
days prior to study entry.
Exclusion Criteria:
- Child in care.
- Use of any investigational or non-registered product other than the study vaccine(s)
during the period starting 30 days before the day of study vaccination or planned use
during the entire study period.
- Concurrently participating in another clinical study, in which the child has been or
will be exposed to an investigational or a non-investigational product. Chronic
administration of immunosuppressants, or other immune-modifying drugs during the
period starting 180 days prior to the first vaccine dose or any planned administration
of immunosuppressive and immune-modifying drugs during the entire study.
- Inhaled and topical steroids are allowed.
- Planned administration / administration of a vaccine not foreseen by the study
protocol during the period starting 30 days prior to study vaccination at Visit 1 and
ending at Visit 2 (or ending at Visit 3 for the US post-dose 2 sub-cohort). Please
Note:
- Inactivated influenza (Flu) vaccine and Haemophilus influenzae type b conjugate
vaccine (Hib) vaccines may be given at any time during the study, including the
day of study vaccination (Flu and Hib vaccines must be administered at a
different location than the study vaccine/s).
- Any age appropriate vaccine may be given starting at Visit 2 (or starting at
Visit 3 for the US post-dose 2 sub-cohort), and anytime thereafter.
- Administration of immunoglobulins and/or any blood products during the period starting
180 days prior to study vaccination at Visit 1 or planned administration from the date
of vaccination through the immunogenicity evaluation at Visit 2, or at Visit 3 for the
US post-dose 2 sub-cohort.
- History of measles, mumps, rubella, varicella/zoster and/or hepatitis A diseases.
- Known exposure to measles, mumps, rubella and/or varicella/zoster during the period
starting 30 days prior to the first study vaccination.
- Previous vaccination against measles, mumps, rubella, hepatitis A and/or varicella
virus.
- Any confirmed or suspected immunosuppressive or immunodeficient condition, based on
medical history and physical examination.
- A family history of congenital or hereditary immunodeficiency.
- History of allergic disease or reactions likely to be exacerbated by any component of
the vaccines, including hypersensitivity to neomycin, latex or gelatin.
- Blood dyscrasias, leukemia, lymphomas of any type, or other malignant neoplasms
affecting the bone marrow or lymphatic systems.
- Acute disease at the time of enrollment. Acute disease is defined as the presence of a
moderate or severe illness with or without fever. Fever is defined as temperature
≥38°C/100.4°F by any age appropriate route. All vaccines can be administered to
persons with a minor illness such as diarrhea, mild upper respiratory infection
without fever.
- Active untreated tuberculosis based on medical history.
- Any other condition which, in the opinion of the Investigator, prevents the child from
participating in the study.
For US children only:
• A child that previously received a fourth dose of any pneumococcal conjugate vaccine.
We found this trial at
52
sites
Click here to add this to my saved trials

Click here to add this to my saved trials

Click here to add this to my saved trials

Click here to add this to my saved trials

Click here to add this to my saved trials

Click here to add this to my saved trials

Click here to add this to my saved trials

Click here to add this to my saved trials

Click here to add this to my saved trials

Click here to add this to my saved trials

Click here to add this to my saved trials

Click here to add this to my saved trials

Click here to add this to my saved trials

Click here to add this to my saved trials

Click here to add this to my saved trials

Click here to add this to my saved trials

Click here to add this to my saved trials

Click here to add this to my saved trials

Click here to add this to my saved trials

Click here to add this to my saved trials

Click here to add this to my saved trials

Click here to add this to my saved trials

Click here to add this to my saved trials

Click here to add this to my saved trials

Click here to add this to my saved trials

Click here to add this to my saved trials

Click here to add this to my saved trials

Click here to add this to my saved trials

Click here to add this to my saved trials

Click here to add this to my saved trials

Click here to add this to my saved trials

Click here to add this to my saved trials

Click here to add this to my saved trials

Click here to add this to my saved trials

Click here to add this to my saved trials

Click here to add this to my saved trials

Click here to add this to my saved trials

Click here to add this to my saved trials

Click here to add this to my saved trials

Click here to add this to my saved trials

Click here to add this to my saved trials

Click here to add this to my saved trials

Click here to add this to my saved trials

Click here to add this to my saved trials

Click here to add this to my saved trials

Click here to add this to my saved trials

Click here to add this to my saved trials

Click here to add this to my saved trials

Click here to add this to my saved trials

Click here to add this to my saved trials

Click here to add this to my saved trials

Click here to add this to my saved trials
